Therapeutic Asset Ratings
534 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
tr128
Cancer
Tarapeutics Science Inc.
P1
C
(36)
tr64
Cancer
Tarapeutics Science Inc.
P1
C
(36)
TRX-920
Cancer
TaiRx, Inc.
P1
C
(36)
tt-00973-ms tablets treatment
Cancer
TransThera Sciences (Nanjing), Inc.
P1
C
(36)
Twp-101
Cancer
Shandong TheraWisdom Biopharma Co., Ltd.
P1
C
(36)
Uct-03-008
Cancer
1200 Pharma, LLC
P1
C
(36)
Utidelone
Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
P1
C
(36)
Valemetostat
Cancer
Daiichi Sankyo
P1
C
(36)
vax014
Cancer
Vaxiion Therapeutics
P1
C
(36)
vg2025
Cancer
M.D. Anderson Cancer Center
P1
C
(36)
Vsv-02
Cancer
The First Affiliated Hospital of Xinxiang Medical College
P1
C
(36)
Wm-A1-3389
Cancer
Wellmarker Bio
P1
C
(36)
Wtx-124
Cancer
Werewolf Therapeutics, Inc.
P1
C
(36)
xb628
Cancer
Exelixis
P1
C
(36)
Xirestomig
Cancer
Antengene (Hangzhou) Biologics Co., Ltd.
P1
C
(36)
xl309
Cancer
Exelixis
P1
C
(36)
xt-0528
Cancer
Xenthera, Inc.
P1
C
(36)
Xzb-0004
Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
P1
C
(36)
yl-17231
Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
P1
C
(36)
yl217
Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
P1
C
(36)
yy201
Cancer
Shanghai Yuyao Biotech Co., Ltd.
P1
C
(36)
Zedoresertib
Cancer
Debiopharm International SA
P1
C
(36)
zg0895 hydrochloride for
Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1
C
(36)
Zirconium Zr 89-Dfo-Ys5
Cancer
Robert Flavell, MD, PhD
P1
C
(36)
zx-4081
Cancer
Nanjing Zenshine Pharmaceuticals
P1
C
(36)
Showing 476 to 500 of 534 assets
Previous
Page 20 of 22
Next
